Get started
LIFE HEALTHC GRP HLDGS LTDLIFE HEALTHC GRP HLDGS LTDLIFE HEALTHC GRP HLDGS LTD

LIFE HEALTHC GRP HLDGS LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

LHC trade ideas

Our opinion on the current state of LIFEHC(LHC)Life Healthcare (LHC) is the second-largest, JSE main-board listed, healthcare company with private hospitals, same-day clinics and surgeries and healthcare companies in South Africa, the UK (Alliance Medical), and Western Europe. The out-going CEO, Shrey Viranna, says that the group is trying to diversify away from conventional hospitals more towards day-clinics and non-acute services. It is also trying to diversify away from medical aid schemes towards people who pay for their medical attention out of their own pockets. They have launched MyLife Clinic which offers a consultation and basic medication for R300. In its results for the year to 30th September 2023 the company reported revenue up 10,3% and headline earnings per share (HEPS) down 16,9%. The company said, "The Group's SA operations experienced strong demand for their services in the current year driven by the Group being the preferred network provider for medical aids. This led to higher utilisation of the Group's hospitals and complementary services which delivered PPD growth of 9.5%." In a trading statement for the six months to 31st March 2024 the company estimated that earnings per share would increase by more than 20% due to the disposal of Alliance Medical Group. This will not affect HEPS, however. In its results for the year to 30th September 2024 the company reported revenue up 12,7% and headline earnings per share (HEPS) up 73,4%. The company said, "NEPS, which excludes non-trading related items, increased by 48.5% to 132.3 cents (2023: 89.1 cents). The LMI RM2 transaction contributed 30.1 cents net after tax." In a trading statement for the six months to 31st March 2025 the company estimated that it would make a headline loss of between 150,9c and 158,7c compared with a profit of 65,2c in the previous period. Technically, the share peaked at R47 in September 2014 and then entered a long downward trend. It is now trading for around 1380c and is on a P:E of 10,6. The multiple reflects the share's defensive nature and its overseas diversification – which gives it some rand-hedge characteristics. It has not yet broken up through its long-term downward trendline. In our view, this share looks like reasonable value.
JSE:LHC
by PDSnetSA
Our opinion on the current state of LIFEHC(LHC)Life Healthcare (LHC) is the second-largest JSE-listed healthcare company, operating private hospitals, same-day clinics, and healthcare services in South Africa, the UK (through Alliance Medical), and Western Europe. The outgoing CEO, Shrey Viranna, highlighted the group's strategic shift towards day-clinics and non-acute services, along with a focus on self-pay patients rather than solely relying on medical aid schemes. This is evident from their launch of MyLife Clinic, which offers consultations and basic medication for R300. In its results for the year ending 30th September 2023, the company reported revenue growth of 10.3%, although headline earnings per share (HEPS) fell by 16.9%. The company attributed strong demand in its South African operations to being a preferred provider for medical aids, resulting in a 9.5% growth in paid patient days (PPD). For the six months ending 31st March 2024, the company projected earnings per share to increase by over 20% due to the sale of Alliance Medical Group, although this did not impact HEPS. The half-year results showed revenue growth of 7.8% and a 2.3% increase in PPD for acute services. HEPS from continuing operations rose by 29.9%. The company also noted a strong financial position with net debt reduced to a ratio of 0.8 times normalised EBITDA after paying a special dividend in April 2024. In an update for the full year to 30th September 2024, Life Healthcare reported revenue growth of between 12% and 13%, with PPD increasing by 1.6%. The company estimated that HEPS from continuing operations would rise by 55.9% to 60.9%. It highlighted significant debt repayment and a reduction in interest costs by approximately 66% due to positive cash flow from the sale of Alliance Medical. Technically, the share peaked at R47 in September 2014 but entered a long downward trend. It is currently trading around 1700c with a price-to-earnings (P:E) ratio of 20.74. This valuation reflects the company's defensive nature, expected financial improvements, and its overseas diversification, which provides some rand-hedge benefits. Although the share has not yet broken through its long-term downward trendline, it appears to offer reasonable value, especially as dividends have resumed.
JSE:LHC
by PDSnetSA
UPDATE: Life Health Care exceeded our targets big timeLife Health Care was presenting a simple Head and Shoulders with a usual drop for a short. The price started off well then went to the entry. Wake up and not only did it go past R15.96 target... The market opened aty R10.80 exceeding our expectations and profits. It's these trades that we absolutely love and can't help but get excited when things go extraordinary to our favour. Now there is a W Formation and the price has broken up. So looking at a Medium Probability setup, we can expect the price to head to R14.29.
JSE:LHCLong
by Timonrosso
Our opinion on the current state of LIFEHC(LHC)Life Healthcare (LHC) is the second-largest healthcare company listed on the JSE main board, operating private hospitals, same-day clinics, surgeries, and healthcare companies in South Africa, the UK (Alliance Medical), and Western Europe. The outgoing CEO, Shrey Viranna, has indicated that the group is shifting its focus from conventional hospitals to day clinics and non-acute services. Additionally, there is an effort to diversify from reliance on medical aid schemes towards serving individuals who pay for medical services out of pocket. This is exemplified by the launch of MyLife Clinic, which offers consultations and basic medication for R300. In its annual results for the year ending 30th September 2023, Life Healthcare reported a revenue increase of 10.3% but a decrease in headline earnings per share (HEPS) by 16.9%. The company attributed this performance to "The Group's SA operations experienced strong demand for their services in the current year driven by the Group being the preferred network provider for medical aids. This led to higher utilisation of the Group's hospitals and complementary services which delivered PPD growth of 9.5%." For the six months ending 31st March 2024, a trading statement projected that earnings per share would increase by more than 20%, a boost largely due to the disposal of Alliance Medical Group. However, this disposal would not impact HEPS. The subsequent results for this period reflected a revenue increase of 7.8% and a 2.3% rise in paid patient days (PPD) in the acute section. HEPS from continuing operations saw a significant increase of 29.9%. The company noted, "The Group is in a net cash position as at 31 March 2024 due to the proceeds received from the sale of AMG. The Group remains in a strong financial position with net debt to normalized EBITDA (as per bank covenant definitions) of 0.8 times after the payment of the special dividend on 8 April 2024." Technically, Life Healthcare’s shares peaked at R47 in September 2014 but have since been in a long downward trend. Currently trading around 1130c, the shares have a P/E ratio of 13.85, reflecting the company's expectation of improved results, its defensive nature, and its overseas diversification, which offers some rand-hedge characteristics. Given these factors, Life Healthcare shares appear to offer reasonable value, particularly now that the company has resumed paying dividends. This positions the shares as a potentially attractive option for investors looking for exposure in the healthcare sector with a blend of local and international operations.
JSE:LHC
by PDSnetSA
Our opinion on the current state of LIFEHC(LHC)Life Healthcare (LHC) is a major player in the healthcare sector, listed on the JSE, operating private hospitals, day clinics, and healthcare services across South Africa, the UK, and Western Europe. The company is strategically shifting from traditional hospitals to day-clinics and non-acute services, and broadening its customer base beyond those covered by medical aids to include out-of-pocket payers. This pivot includes initiatives like MyLife Clinic, offering affordable medical consultations. For the fiscal year ending September 30, 2023, Life Healthcare reported a 10.3% increase in revenue, though headline earnings per share (HEPS) fell by 16.9%. This was attributed to robust demand within its South African operations and preferred provider status with medical aids, boosting hospital utilization and services. A recent trading update for the first half of fiscal 2024 indicated a projected EPS increase of over 20% following the sale of Alliance Medical Group. However, this transaction will not impact HEPS. Operational updates for the same period showed revenue growth of 7-8% and a 2.3% rise in paid patient days (PPD) for acute services, though normalized EBITDA from continuing operations was expected to drop by 2.3%-3.3%. From a technical perspective, Life Healthcare's share price has been in a long-term decline since peaking at R47 in September 2014, currently trading around 1004c with a P/E ratio of 15.83. This valuation reflects anticipated improvements in performance, the defensive nature of the healthcare sector, and the company's international diversification, which offers some protection against rand volatility. The company is also looking to expand its footprint significantly by acquiring 51 clinics in South Africa, Eswatini, and Namibia within the next year, signaling continued growth and diversification efforts. Despite a sideways trend in its share price, Life Healthcare appears to be a reasonable value proposition, especially with the resumption of dividend payments.
JSE:LHC
by PDSnetSA
Our opinion on the current state of LHCLife Healthcare, as the second-largest healthcare company listed on the Johannesburg Stock Exchange (JSE), operates an extensive network of private hospitals, same-day clinics, surgeries, and healthcare companies across South Africa, the UK (through Alliance Medical), and Western Europe. The company's strategic direction, as outlined by outgoing CEO Shrey Viranna, focuses on diversifying from traditional hospital care towards day-clinics and non-acute services, alongside broadening its customer base beyond medical aid beneficiaries to include individuals paying out-of-pocket for medical services. Initiatives like the MyLife Clinic, offering consultations and basic medication for R300, exemplify this shift. For the fiscal year ending 30th September 2023, Life Healthcare reported a 10.3% increase in revenue, although headline earnings per share (HEPS) saw a decline of 16.9%. The company attributed the robust demand for its services in South Africa to its status as the preferred network provider for medical aids, leading to increased hospital and complementary service utilization. A significant development was the trading statement for the six months ending 31st March 2024, projecting an earnings per share increase of over 20% following the disposal of Alliance Medical Group. This disposal is expected to impact earnings per share positively but will not influence HEPS. From a technical analysis perspective, the share experienced its peak at R47 in September 2014, subsequently entering a prolonged downtrend and currently trading around 1791c with a price-to-earnings (P:E) ratio of 20.31. This valuation mirrors investor expectations for improved results, the company's defensive market position, and its international diversification, offering some protection against rand volatility. Despite the sideways trend in its share price, Life Healthcare's decision to resume dividend payments, combined with its strategic acquisitions, such as the planned acquisition of 51 clinics in South Africa, Eswatini, and Namibia as reported by Business Day on 19th May 2023, positions it as a potentially valuable investment. These moves indicate the company's commitment to expansion and adaptation in a changing healthcare landscape, making Life Healthcare a consideration for investors seeking exposure to the healthcare sector with a diversified and evolving operational model.
JSE:LHC
by PDSnetSA
LHCMedium term view. Buy at current levels or better/lower. The group has announced the fulfilment of conditions precedent in respect of it's disposal of it's interest in Alliance Medical Group, which could unlock value for shareholders. Technically, we recently saw a price gap being closed, with a base subsequently having developed. The share could develop a minor pullback before a continuation of the bullish reversal. Time Stop: 10 May 2024. TRADING LEVELS: Entry: 1859 Target: 2047 Stop-loss: 1741
JSE:LHCLong
by techpers
Our opinion on the current state of LHCLife Healthcare (LHC) is the second-largest, JSE main-board listed, healthcare company with private hospitals, same-day clinics and surgeries and healthcare companies in South Africa, the UK (alliance Medical) and Western Europe. The out-going CEO, Shrey Viranna, says that the group is trying to diversify away from conventional hospitals more towards day-clinics and non-acute services. It is also trying to diversify away from medical aid schemes towards people who pay for their medical attention out of their own pockets. They have launched MyLife Clinic which offers a consultation and basic medication for R300. In its results for the year to 30th September 2023 the company reported revenue up 10,3% and headline earnings per share (HEPS) down 16,9%. The company said, "The Group's SA operations experienced strong demand for their services in the current year driven by the Group being the preferred network provider for medical aids. This led to higher utilisation of the Group's hospitals and complementary services which delivered PPD growth of 9.5%". Technically, the share peaked at R47 in September 2014 and then entered a long downward trend. It is now trading for around 1758c and is on a P:E of 19,93. The multiple reflects the company's expectation of improved results, its defensive nature, and its overseas diversification - which gives it some rand-hedge characteristics. In our view, this share looks like reasonable value, especially now that it is paying dividends again, but the trend remains downwards. On 19th May 2023 Business Day reported that Life is acquiring 51 clinics in South Africa, Eswatini and Namibia over the next year.
JSE:LHC
by PDSnetSA
LHCFriday 17-November-2023, 06h30 Life Healthcare (LHC, 1756c) Yesterday the share sold off sharply (-7.56%) on the back of it's results. Technically, here are two items to note: (1) the gap created on 15 February is close to be filled and (2) the Tactical Trading Guide for both the short and medium term time frames state the following: "Reward-to-risk becoming attractive for a buy/long position". It's possible that the share continues to weak however it may be worth keeping in mind the two aforementioned factors for a potential bullish reversal trade. I'm placing this name on my watchlist.
JSE:LHC
by techpers
LHCA chart from today's report (zoomed in slightly vs the one in my report). For more research insights, including trade ideas, get in touch today. LIFE HEALTHCARE (LHC, 2130c) | Daily Chart | Monday, 31 July 2023 (Pre-Market) | The share is trading just below it’s 52-week high, having absorbed the multi-month overhead supply. Preceding the short term advance, was the share finding triple support at the rising 200-day simple moving average. A weekly close above 2130c would mean a breakout and sets up the share for further upside, with long term targets of 2430c and 2517c. PORTFOLIO VIEW
JSE:LHC
by techpers
Life Health showing recovering finallyInv Head and Shoulders has been anticipated for months. We were just waiting for the right shoulder to form, which it has done. Next we'll need the price to close above the neckline and it should be a strong trade to buy, hold and profit. Price >200 RSI>50 Target R23.78 ABOUT THE COMPANY Life Healthcare Group is a South Africa-based healthcare provider. Origins: Life Healthcare, formerly known as Afrox Healthcare, was established in 1983. It is one of the largest private hospital operators in South Africa. Healthcare Services: Life Healthcare Group operates hospitals, provides acute care, and offers chronic disease management, among other services. It is involved in the entire healthcare spectrum, from wellness to acute interventions to rehabilitation. Global Presence: Apart from South Africa, Life Healthcare has extended its services to other countries such as Poland (through Scanmed) and India (through Max Healthcare). Large Hospital Network: Life Healthcare operates 66 healthcare facilities, including hospitals and day clinics, across South Africa. Employment: Life Healthcare Group is a significant employer, with more than 18,000 employees, contributing substantially to the local economy. Public Trading: Life Healthcare has been listed on the Johannesburg Stock Exchange since 2010.
JSE:LHCLong
by Timonrosso
Life health in good form to R23.78 Inv Head and Shoulders has formed for LHC. We just need the final right shoulder to form, break up and out of the pattern. Then we will see buying take over, driving the price up. Price >200 RSI>50 Target 1 will be R23.78 ABOUT THE COMPANY Life Healthcare is one of the largest private hospital operators in South Africa, providing acute hospital care across 64 facilities. H Establishment: Life Healthcare was established in 1983 and has grown to become a leading provider of private healthcare in South Africa. Global Presence: Apart from South Africa, it also has operations in other countries including Poland, through its subsidiary Scanmed, and in India through Max Healthcare. Service Range: The company offers a wide range of services including acute hospital care, mental health, renal dialysis, occupational health, employee wellness, and chronic disease management. Workforce: The company employs over 18,000 people and had more than 1,600 admitting doctors. Patient-Oriented Approach: Life Healthcare emphasizes a patient-centered approach and is committed to providing quality care to all patients.
JSE:LHCLong
by Timonrosso
Life Health showing downside to R16.23 but with a warning!Inverse Reverse C and H has formed on Life Health. The price did close below the brim level which also happened to be on the 200MA. This is a big test for the company. Once the price breaks below 200MA, there is a high chance of it closing the gap and dropping further. 21>7 Price -200 - Test RSI<50 - lower highs Target R16.23 It is a medium probability trade to take on. ABOUT THE COMPANY Establishment: Life Healthcare Group Holdings Ltd, often simply known as Life Healthcare, is a South Africa-based company that was founded in 1983. Healthcare Provider: Life Healthcare is a leading private hospital operator in South Africa. It offers acute hospital care, acute mental healthcare, renal dialysis, and acute rehabilitation, among other services. International Presence: Life Healthcare has an international footprint and operates in various countries including India through Max Healthcare, and the United Kingdom through Alliance Medical. Expansion into Diagnostic Imaging: Life Healthcare expanded its healthcare offering in 2016 with the acquisition of Alliance Medical, which is a leading independent provider of medical imaging services within Europe.
JSE:LHCShort
by Timonrosso
TARGET REACHED: Life Health struck our target 1 at R21.34 W Formation formed, we then had some high volatility around the price. Luckily, the stop loss would have been below the pattern. The indicators were all showing bullish signs. 7>21>200 RSI>50 Target struck at R21.34 ABOUT THE COMPANY Life Healthcare Group Holdings Limited was founded in 1983 and is headquartered in Johannesburg, South Africa. Life Healthcare is one of the largest private healthcare providers in South Africa, operating 66 hospitals and healthcare facilities across the country. The company employs over 19,000 people and serves over 4 million patients per year. Life Healthcare provides a wide range of medical services, including acute hospital care, mental health services, renal dialysis, and oncology care. Life Healthcare has a partnership with the South African National Blood Service to support blood donation drives and increase awareness about the importance of blood donation.
JSE:LHCLong
by Timonrosso
Life Health Care group showing strong upside to R21.39 WARNINGW Formation since Sep 2022. It's been moving in a sideways range without any promising direction. Then in February we had a breakaway gap. This is where the price jumped from the sideways range into an uptrend. And most sellers and stop losses were hit. This showed strong upside to come. 7>21>200 RSI>50 Target R21.39 WARNING Gaps like to close 70% of the time. And I don't generally like taking any trades where there are prior gaps. I'd take this trade as a medium probability one.
JSE:LHCLong
by Timonrosso
$JSELHC - Life Healthcare: Is This The Breakout That Bucks Bear?Life Healthcare stock peaked way back in 2014 around 4400 and has endured one the longest bear trends on the JSE. The hospital sector did not catch tailwinds in the post covid-19 crash everything rally. The share did catch a bid between December 2020 to June 2021 rallying from 1500 to 2820, though i must add cautiously, this rally looks to have unfolded in three waves and not five. From the 2820 peak, the stock has been in a strong correction characterized by lower highs (LH) and lower lows (LL). The lower low trend changed from the 1597 bottom and the stock started making higher lows (HL) which are signs of a turnaround. Today, Life Healthcare released a trading update for the four months ended 31 January 2023 with a cautionary announcement on having received several unsolicited proposals from third parties to acquire AMG. AMG is a core, wholly owned subsidiary. The market liked the update which saw the share gap up at open and trade strongly intraday. At the time of writing, the share is up over 13%. What is significant technically is the share has broken above a key resistance trendline, made a new higher high relative to 1910 though the weekly candle has not closed yet. Markets can react strongly to such proposals but can react equally negatively should the proposal not go through so until there's further announcements, trade cautiously and watch price action at the trendline.
JSE:LHC
by Loyiso_BlaqueSoros_Mpeta